1. Home
  2. PRTA vs LIND Comparison

PRTA vs LIND Comparison

Compare PRTA & LIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • LIND
  • Stock Information
  • Founded
  • PRTA 2012
  • LIND 1979
  • Country
  • PRTA Ireland
  • LIND United States
  • Employees
  • PRTA N/A
  • LIND N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • LIND Transportation Services
  • Sector
  • PRTA Health Care
  • LIND Consumer Discretionary
  • Exchange
  • PRTA Nasdaq
  • LIND Nasdaq
  • Market Cap
  • PRTA 643.0M
  • LIND 742.0M
  • IPO Year
  • PRTA N/A
  • LIND N/A
  • Fundamental
  • Price
  • PRTA $13.77
  • LIND $12.16
  • Analyst Decision
  • PRTA Buy
  • LIND Strong Buy
  • Analyst Count
  • PRTA 7
  • LIND 4
  • Target Price
  • PRTA $46.50
  • LIND $14.25
  • AVG Volume (30 Days)
  • PRTA 711.1K
  • LIND 258.1K
  • Earning Date
  • PRTA 02-13-2025
  • LIND 02-26-2025
  • Dividend Yield
  • PRTA N/A
  • LIND N/A
  • EPS Growth
  • PRTA N/A
  • LIND N/A
  • EPS
  • PRTA N/A
  • LIND N/A
  • Revenue
  • PRTA $133,350,000.00
  • LIND $621,478,000.00
  • Revenue This Year
  • PRTA $56.89
  • LIND $12.55
  • Revenue Next Year
  • PRTA N/A
  • LIND $9.88
  • P/E Ratio
  • PRTA N/A
  • LIND N/A
  • Revenue Growth
  • PRTA N/A
  • LIND 10.56
  • 52 Week Low
  • PRTA $11.70
  • LIND $6.35
  • 52 Week High
  • PRTA $34.75
  • LIND $14.34
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 48.19
  • LIND 52.51
  • Support Level
  • PRTA $12.39
  • LIND $11.41
  • Resistance Level
  • PRTA $13.64
  • LIND $12.35
  • Average True Range (ATR)
  • PRTA 1.03
  • LIND 0.61
  • MACD
  • PRTA -0.02
  • LIND 0.03
  • Stochastic Oscillator
  • PRTA 40.47
  • LIND 83.90

About PRTA Prothena Corporation plc

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

About LIND Lindblad Expeditions Holdings Inc.

Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of nine owned expedition ships and five seasonal charter vessels under the Lindblad brand.

Share on Social Networks: